Print  |  Close

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)


Active: Yes
Cancer Type: Quality of Life NCT ID:
Trial Phases: Protocol IDs: DCP-001 (primary)
Eligibility: All Ages, Male and Female Study Type: Health services research
Study Sponsor:
NCI Full Details:

Summary

Phase: Other

Participating Research Bases-ALLIANCE, COG, ECOG-ACRIN, NRG, SWOG, URCC, WAKE

CANCER TYPE: Any Site
RESEARCH BASE: NCI
 
 
 
BRIEF DESCRIPTION
 
Screening tool used to collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled in cancer control studies.
 
 
NOTES
 
 
All potential study participants must be asked to participate in the screening tool study at the time they are screened for a cancer control or prevention trial.
 
Patients can be registered to DCP-001 once eligibility for and enrollment status to the trial for which the patient is being screened has been determined.
 
Patients may still be registered to DCP-001, even if they have been deemed ineligible for the cancer control study.
 
Participants may be screened for more than one cancer control and prevention trial.
 
The questionnaire may be accessed under the link for Consent Form 2 above.
 
The patient script and talking points may be accessed under the link for Consent Form 3 above.
 
 
 
ELIGIBILITY
 
All patients (pediatric and adults) screened for selected NCORP trials supported by the Division of Cancer Prevention (DCP). These trials include symptom and toxicity management, prevention, screening, post-treatment surveillance and comparative effectiveness. Cancer care delivery clinical trials will be included if the primary aim focuses on a patient intervention. A screened patient will be defined as one meeting the following minimum eligibility criteria per the protocol being screened for:  
  • Cancer diagnosis including stage and histology or pre-malignancy
  • Age range specified in the protocol for which the patient is being screened
  • Indication for the study intervention (e.g., symptom, toxicity)
  • A legally authorized representative may consent for a participant with impaired decision making.
 

Treatment Sites in Georgia

Cancer Center at DeKalb Medical Center
2675 North Decatur Road
Suite 410
Decatur, GA 30033
404-501-7789
www.dekalbmedical.org



Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.